-
EP4313295
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4313295
| EP4313295 - PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 05.01.2024 Database last updated on 24.08.2024 | |
| Former | The international publication has been made Status updated on 30.09.2022 | ||
| Former | unknown Status updated on 03.05.2022 | Most recent event Tooltip | 31.05.2024 | Change: Validation states | published on 03.07.2024 [2024/27] | 31.05.2024 | Change - extension states | published on 03.07.2024 [2024/27] | Applicant(s) | For all designated states Almac Discovery Limited Almac House 20 Seagoe Industrial Estate Craigavon BT63 5QD / GB | [2024/06] | Inventor(s) | 01 /
ROUNTREE, James Samuel Shane Craigavon BT63 5QD / GB | 02 /
WHITEHEAD, Steven Kristopher Craigavon BT63 5QD / GB | 03 /
SHEPHERD, Steven David Craigavon BT63 5QD / GB | 04 /
HELM, Matthew Duncan Craigavon BT63 5QD / GB | 05 /
BURKAMP, Frank Craigavon BT63 5QD / GB | 06 /
O'DOWD, Colin Craigavon BT63 5QD / GB | 07 /
HARRISON, Timothy Craigavon BT63 5QD / GB | [2024/06] | Representative(s) | Boult Wade Tennant LLP Salisbury Square House 8 Salisbury Square London EC4Y 8AP / GB | [2024/06] | Application number, filing date | 22718158.3 | 24.03.2022 | [2024/06] | WO2022EP57820 | Priority number, date | GB20210004097 | 24.03.2021 Original published format: GB 202104097 | [2024/06] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022200523 | Date: | 29.09.2022 | Language: | EN | [2022/39] | Type: | A1 Application with search report | No.: | EP4313295 | Date: | 07.02.2024 | Language: | EN | The application published by WIPO in one of the EPO official languages on 29.09.2022 takes the place of the publication of the European patent application. | [2024/06] | Search report(s) | International search report - published on: | EP | 29.09.2022 | Classification | IPC: | A61P3/04, A61P3/10, A61P21/00, C07D401/06, C07D401/14, C07D487/04, C07D491/048, C07D495/04, A61K31/4545 | [2024/06] | CPC: |
C07D401/06 (EP,IL,KR);
C07D401/14 (EP,IL,KR);
A61K31/4545 (KR);
A61K31/496 (KR);
A61K31/513 (KR);
A61K31/517 (KR);
A61P21/00 (EP,IL,KR);
A61P3/04 (EP,IL,KR);
A61P3/10 (EP,IL,KR);
C07D409/14 (KR);
C07D413/14 (KR);
C07D471/04 (KR);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2024/06] | Title | German: | PHARMAZEUTISCHE VERBINDUNGEN ALS INHIBITOREN DER UBIQUITINSPEZIFISCHEN PROTEASE 19 (USP14) | [2024/06] | English: | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | [2024/06] | French: | COMPOSÉS PHARMACEUTIQUES UTILES EN TANT QU'INHIBITEURS DE LA PROTÉASE SPÉCIFIQUE DE L'UBIQUITINE 19 (USP19) | [2024/06] | Entry into regional phase | 23.10.2023 | National basic fee paid | 23.10.2023 | Designation fee(s) paid | 23.10.2023 | Examination fee paid | Examination procedure | 23.10.2023 | Examination requested [2024/06] | 23.10.2023 | Date on which the examining division has become responsible | 10.05.2024 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 23.10.2023 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [X]WO2016126935 (FORMA THERAPEUTICS INC [US]) [X] 1-3,6,64,65 * Formulas (I),(Ia),(Ib),(Ic);; claims 1,11,12,13,21 *; | [X]WO2016126926 (FORMA THERAPEUTICS INC [US]) [X] 1-3,6,64,65 * claims 1,2,4-10,21 *; | [X]WO2016126929 (FORMA THERAPEUTICS INC [US]) [X] 1-3,6,64,65 * claims 1,11,12,21,25,26 *; | [X]WO2019067503 (DANA FARBER CANCER INST INC [US]) [X] 1-3,6,64,65 * page 48; compound 2 * * Biological assays;; table 3 *; | [ID]WO2019150119 (ALMAC DISCOVERY LTD [GB]) [ID] 1-68 * the whole document ** Examples used for comparison purposes Examples provided;; examples 278,287; claims 1-51 *; | [ID]WO2020115501 (ALMAC DISCOVERY LTD [GB]) [ID] 1-68 * Example used for comparison purposes Examples provided;; example 397; claims 1-63 *; | [ID]WO2020115500 (ALMAC DISCOVERY LTD [GB]) [ID] 1-68 * Example used for comparison purposes Examples provided;; example 255; claims 1-56 * | by applicant | WO2018020242 | WO2019150119 | WO2020115501 | WO2020115500 | - HOELLER D. et al., Nat. Rev. Cancer, (20060000), vol. 6, pages 776 - 788 | - GAO et al., J. Physiol., Pharmacol., (20060000), vol. 84, pages 5 - 14 | - LOOSDREGT J. et al., Immunity, (20130000), vol. 39, pages 259 - 271 | - RUBINSZTEIN D. et al., Nature, (20060000), vol. 443, pages 780 - 786 | - WANG J. et al., J. Cell Immunol., (20060000), vol. 3, pages 255 - 261 | - CORN J. et al., Nat. Struct. & Mol. Biol., (20140000), vol. 21, pages 297 - 300 | - NICHOLSON B. et al., Cell Biochem. Biophys., (20130000), vol. 60, pages 61 - 68 | - KOMANDER D. et al., Nat. Rev. Mol., (20090000), vol. 10, pages 550 - 563 | - CLAGUE M. et al., Physiol. Rev., (20130000), vol. 93, pages 1289 - 1315 | - COLLAND F. et al., Biochimie, (20080000), vol. 90, pages 270 - 283 | - LEE J. et al., J. Biol. Chem., (20140000), vol. 289, pages 3510 - 3507 | - LEE J. et al., Nat. Cell Biol, (20160000), vol. 18, pages 765 - 776 | - HASSINK B. et al., EMBO J., (20090000), vol. 10, pages 755 - 761 | - LEE J. et al., Nat. Cell Biol., (20160000), vol. 18, pages 765 - 776 | - NAKAMURA N. et al., Exp. Cell Res., (20140000), vol. 328, pages 207 - 216 | - HARADA K. et al., Int. J. Mol. Sci., (20160000), vol. 17, page E1829 | - ALTUN M. et al., J. Biol. Chem., (20120000), vol. 287, pages 1962 - 1969 | - VELASCO K. et al., Biochem. Biophys. Res. Commun., (20130000), vol. 433, pages 390 - 395 | - LU Y. et al., Mol. Cell Biol., (20090000), vol. 29, pages 547 - 558 | - LU L. et al., PLoS ONE, (20110000), vol. 6, page e15936 | - OGAWA M. et al., J. Biol. Chem., (20110000), vol. 286, pages 41455 - 41465 | - JIN S. et al., EMBO J., (20160000), vol. 35, pages 866 - 880 | - CUI J. et al., Autophagy, (20160000), vol. 12, pages 1210 - 1211 | - GU Z. et al., Future Microbiol., (20170000), vol. 12, pages 767 - 779 | - PERRODY E. et al., eLife, (20160000), vol. 5, page e19083 | - WU M. et al., Oncotarget, (20170000), vol. 8, pages 2197 - 2208 | - WING S., Int. J. Biochem. Cell Biol., (20130000), vol. 45, pages 2130 - 2135 | - WING S. et al., Int. J. Biochem. Cell Biol., (20160000), vol. 79, pages 426 - 468 | - WILES B. et al., Mol. Biol. Cell, (20150000), vol. 26, pages 913 - 923 | - COMBARET L. et al., Am. J. Physiol. Endocrinol. Metab., (20050000), vol. 288, pages E693 - 700 | - HE W. et al., PLoS ONE, (20160000), vol. 11, page e0147515 | - BIERI G. et al., Neurobiol Dis., (20180000), vol. 109B, pages 219 - 225 | - LIM K. et al., Oncotarget, (20160000), vol. 7, pages 34759 - 34772 | - COYNE E et al., Diabetologia, (20190000), vol. 62, pages 136 - 146 | - SUNDARAM P. et al., Am. J. Physiol. Endocrinol. Metab., (20090000), vol. 297, pages E1283 - 90 | - OGAWA M. et al., J. Endocrinol., (20150000), vol. 225, pages 135 - 145 | - BEDARD N. et al., FASEB J, (20150000), vol. 29, pages 3889 - 3898 | - J. Org. Chem., (19970000), vol. 62, pages 7512 - 7515 | - Tetrahedron: Asymmetry, (19990000), vol. 10, pages 4231 - 4237 | - Angew. Chem. Int. Ed., (20110000), vol. 50, pages 2734 - 2737 | - Org. Lett., (20140000), vol. 16, pages 1236 - 1239 |